Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Viet-thi Tran"'
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background The objective of the study was to identify the psychosocial and contextual markers considered by physicians to personalize care. Methods An online questionnaire with one open-ended question, asking physicians to describe clinical
Externí odkaz:
https://doaj.org/article/c9f75325f46c402fb2368620be551a23
Autor:
Raphaël Porcher, Philippe Ravaud, Isabelle Boutron, Viet-Thi Tran, Sally Yaacoub, Anna Pellat, Linda Gough, Hillary Bonnet
Publikováno v:
BMJ Medicine, Vol 3, Iss 1 (2024)
Objective To examine the characteristics of comparative non-randomised studies that assess the effectiveness or safety, or both, of drug treatments.Design Cross sectional study.Data sources Medline (Ovid), for reports published from 1 June 2022 to 31
Externí odkaz:
https://doaj.org/article/2a776e95ebb6425c8c81a4df02e20d7f
Autor:
Misk A. Al Zahidy, MS, Sue Simha, BS, Megan Branda, MS, Mariana Borras-Osorio, MD, Maeva Haemmerle, Viet-Thi Tran, MD, PhD, Jennifer L. Ridgeway, PhD, Victor M. Montori, MD
Publikováno v:
Mayo Clinic Proceedings: Digital Health, Vol 3, Iss 1, Pp 100180- (2025)
Objective: To understand the contribution of digital medicine tools (eg, continuous glucose monitoring systems, scheduling, and messaging applications) to treatment burden in patients with diabetes. Patients and Methods: Between October and November
Externí odkaz:
https://doaj.org/article/3410ee93090b40c68ead851f05ea14f3
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract During the early phase of outbreaks, awareness of the presence of the disease plays an important role in transmission dynamics. To investigate the processes of how people become aware of a disease, we conducted two complementary investigatio
Externí odkaz:
https://doaj.org/article/956fd4afc21046e88e8555775150e34a
Publikováno v:
International Journal of Infectious Diseases, Vol 133, Iss , Pp 67-74 (2023)
Objectives: We aimed to identify trajectories of the evolution of post-COVID-19 condition, up to 2 years after symptom onset. Methods: The ComPaRe long COVID e-cohort is a prospective cohort of patients with symptoms lasting at least 2 months after S
Externí odkaz:
https://doaj.org/article/a33717c612da4d4181571ed596fb6280
Publikováno v:
BMJ Medicine, Vol 2, Iss 1 (2023)
Objective To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.Design Target trial emulation based on ComPaRe e-cohort.Data source ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where
Externí odkaz:
https://doaj.org/article/a6ed18ebc6d64c8d975d02c7dcdb5df7
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-6 (2022)
Long-term complications and persistent symptoms occur following COVID-19, but the nature and duration of the long-term symptoms are not fully characterised. Here the authors report the evolution of post COVID-19 symptoms using a validated self-report
Externí odkaz:
https://doaj.org/article/ef0a8b2bd61b4961bc6dd725204bf6a6
Autor:
Arthur James, MD, MSc, Philippe Ravaud, MD, PhD, Carolina Riveros, MSc, Mathieu Raux, MD, PhD, Viet-Thi Tran, MD, PhD
Publikováno v:
Annals of Surgery Open, Vol 3, Iss 4, p e211 (2022)
Background:. To assess the completeness of the collection of patient-important outcomes and the mismatch between outcomes measured in research and patients’ important issues after trauma. Summary Background Data:. To date, severe trauma has mainly
Externí odkaz:
https://doaj.org/article/13c6b4f5a6724867803a805d2b9548ef
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Objectives In France, about 30% of the population refuses COVID-19 vaccination outright, and 9 to 40% are hesitant. We developed and evaluated an interactive web tool providing transparent and reliable information on the benefits and risks o
Externí odkaz:
https://doaj.org/article/9014026b10ef4bc490155df56ea95b15
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-11 (2020)
Abstract Background Wearable biometric monitoring devices (BMDs) have the potential to transform the conduct of randomized controlled trials (RCTs) by shifting the collection of outcome data from single measurements at predefined time points to dense
Externí odkaz:
https://doaj.org/article/b3bcc14aab9944d38770183264230405